Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to compare the steady-state
exposure of semaglutide administered subcutaneously once daily to semaglutide administered
subcutaneously once weekly in healthy subjects.